
Jennifer S Gewandter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1407851/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|---------------------|------------------------|
| 1 | Benefit–risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain, 2022, 163, 1006-1018. | 4.2 | 4 |
| 2 | Partnering with patients in clinical trials of pain treatments: a narrative review. Pain, 2022, 163, 1862-1873. | 4.2 | 6 |
| 3 | Predicting Treatment Response with Sensory Phenotyping in Post-Traumatic Neuropathic Pain. Pain Medicine, 2022, 23, 1726-1732. | 1.9 | 3 |
| 4 | Evaluation of the psychometric properties of patient-reported and clinician-reported outcome measures of chemotherapy-induced peripheral neuropathy: a COSMIN systematic review protocol. BMJ Open, 2022, 12, e057950. | 1.9 | 1 |
| 5 | Systematic Review of Research Methods and Reporting Quality of Randomized Clinical Trials of Spinal Cord Stimulation for Pain. Journal of Pain, 2021, 22, 127-142. | 1.4 | 9 |
| 6 | Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review. Muscle and Nerve, 2021, 63, 170-177. | 2.2 | 22 |
| 7 | Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain Reports, 2021, 6, e895. | 2.7 | 5 |
| 8 | Composite outcomes for pain clinical trials: considerations for design and interpretation. Pain, 2021, 162, 1899-1905. | 4.2 | 35 |
| 9 | Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations. Pain, 2021, 162, 1935-1956. | 4.2 | 38 |
| 10 | Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. Pain, 2021, 162, 2669-2681. | 4.2 | 20 |
| 11 | Evaluating predictors of pain reduction after genicular nerve radiofrequency ablation for chronic knee pain. Pain Management, 2021, 11, 669-677. | 1.5 | 4 |
| 12 | Design and reporting characteristics of clinical trials investigating sedation practices in the paediatric intensive care unit: a scoping review by SCEPTER (Sedation Consortium on Endpoints and) Tj ETQqO | 0 0 1 g8T /(| Dve z lock 10 T |
| 13 | Brain Imaging Biomarkers for Chronic Pain. Frontiers in Neurology, 2021, 12, 734821. | 2.4 | 12 |
| 14 | Peripheral edema: A common and persistent health problem for older Americans. PLoS ONE, 2021, 16, e0260742. | 2.5 | 9 |
| 15 | Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Supportive Care in Cancer, 2020, 28, 2553-2562. | 2.2 | 33 |
| 16 | Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations. Journal of Pain, 2020, 21, 931-942. | 1.4 | 37 |
| 17 | Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial. Supportive Care in Cancer, 2020, 28, 3303-3311. | 2.2 | 23 |

18Estimands and missing data in clinical trials of chronic pain treatments: advances in design and
analysis. Pain, 2020, 161, 2308-2320.4.221

JENNIFER S GEWANDTER

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Idiopathic distal sensory polyneuropathy. Neurology, 2020, 95, 1005-1014. | 1.1 | 49 |
| 20 | When should nonâ€significant results influence clinical decisions?. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 548-549. | 2.3 | 0 |
| 21 | Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials. Pain, 2020, 161, 195-201. | 4.2 | 4 |
| 22 | Comparison of a Pain Tolerability Question With the Numeric Rating Scale for Assessment of Self-reported Chronic Pain. JAMA Network Open, 2020, 3, e203155. | 5.9 | 12 |
| 23 | Overview and critical revision of clinical assessment tools in chemotherapyâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, S13-S25. | 3.1 | 34 |
| 24 | Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. Clinical Pharmacology and Therapeutics, 2019, 106, 204-210. | 4.7 | 24 |
| 25 | Extended-release gabapentin for failed back surgery syndrome: results from a randomized double-blind cross-over study. Pain, 2019, 160, 1029-1036. | 4.2 | 7 |
| 26 | Navigating trials of personalized pain treatments: we're going to need a bigger boat. Pain, 2019, 160, 1235-1239. | 4.2 | 15 |
| 27 | Clinician-rated measures for distal symmetrical axonal polyneuropathy. Neurology, 2019, 93, 346-360. | 1.1 | 19 |
| 28 | Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Supportive Care in Cancer, 2019, 27, 1765-1774. | 2.2 | 29 |
| 29 | Design and Reporting Characteristics of Clinical Trials of Select Chronic and Recurrent Pediatric Pain Conditions: An Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks Systematic Review. Journal of Pain, 2019, 20, 394-404. | 1.4 | 8 |
| 30 | Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 2019, 27, 7-8. | 2.2 | 3 |
| 31 | Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. Pain Reports, 2019, 4, e621. | 2.7 | 26 |
| 32 | The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry Journal of Clinical Oncology, 2019, 37, 11590-11590. | 1.6 | 2 |
| 33 | Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: An ACTTION Systematic Review. Journal of Pain, 2018, 19, 717-726. | 1.4 | 7 |
| 34 | Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Supportive Care in Cancer, 2018, 26, 1019-1028. | 2.2 | 208 |
| 35 | Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. Supportive Care in Cancer, 2018, 26, 1543-1552. | 2.2 | 46 |
| 36 | Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis. Pain, 2018, 159, 2245-2254. | 4.2 | 36 |

JENNIFER S GEWANDTER

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology, 2018, 91, 403-413. | 1.1 | 63 |
| 38 | Why are there no drugs indicated for sciatica, the most common chronic neuropathic syndrome of all?. Drug Discovery Today, 2018, 23, 1904-1909. | 6.4 | 8 |
| 39 | Identifying chemotherapy-induced peripheral neuropathy (CIPN) and its treatment using claims data: A URCC NCORP and NIH Collaboratory study Journal of Clinical Oncology, 2018, 36, e18707-e18707. | 1.6 | 1 |
| 40 | Pretreatment physical activity to predict short- and long-term chemotherapy-induced peripheral neuropathy (CIPN) in a nationwide longitudinal study of paclitaxel for breast cancer Journal of Clinical Oncology, 2018, 36, 10018-10018. | 1.6 | 0 |
| 41 | Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review. Journal of Clinical Epidemiology, 2017, 83, 101-107. | 5.0 | 9 |
| 42 | The ACTTION–APS–AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions. Pain Medicine, 2017, 18, 947-958. | 1.9 | 42 |
| 43 | The ACTTION–APS–AAPM Pain Taxonomy (AAAPT) Multidimensional Approach to Classifying Acute Pain Conditions. Journal of Pain, 2017, 18, 479-489. | 1.4 | 38 |
| 44 | Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations. BMJ Open, 2017, 7, e017288. | 1.9 | 26 |
| 45 | Chemotherapy-induced peripheral neuropathy clinical trials. Neurology, 2017, 89, 859-869. | 1.1 | 37 |
| 46 | Reply. Pain, 2017, 158, 182-183. | 4.2 | 1 |
| 47 | Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?. Pain, 2017, 158, 30-33. | 4.2 | 21 |
| 48 | Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain, 2016, 157, 1836-1850. | 4.2 | 152 |
| 49 | Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTTION Adaptive Choice-Based Conjoint Study. Journal of Pain, 2016, 17, 1198-1206. | 1.4 | 8 |
| 50 | Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. Pain, 2016, 157, 2544-2551. | 4.2 | 16 |
| 51 | Pain intensity rating training. Pain, 2016, 157, 1056-1064. | 4.2 | 48 |
| 52 | Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence, 2016, 158, 1-7. | 3.2 | 49 |
| 53 | Deficiencies in reporting of statistical methodology in recent randomized trials of nonpharmacologic pain treatments: ACTTION systematic review. Journal of Clinical Epidemiology, 2016, 72, 56-65. | 5.0 | 13 |
| 54 | Interpretation of Urine Drug Testing Results in Patients Using Transdermal Buprenorphine Preparations for the Treatment of Chronic Noncancer Pain: Table 1. Pain Medicine, 2015, 16, 1132-1136. | 1.9 | 5 |

JENNIFER S GEWANDTER

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Research design considerations for chronic pain prevention clinical trials. Pain, 2015, 156, 1184-1197. | 4.2 | 115 |
| 56 | Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. Neurology, 2015, 84, 265-272. | 1.1 | 39 |
| 57 | Reporting of Sample Size Calculations in Analgesic Clinical Trials: ACTTION Systematic Review. Journal of Pain, 2015, 16, 199-206.e7. | 1.4 | 32 |
| 58 | Reporting of adverse events and statistical details of efficacy estimates in randomized clinical trials of pain in temporomandibular disorders. Journal of the American Dental Association, 2015, 146, 246-254.e6. | 1.5 | 7 |
| 59 | Evaluation of outcome measures for neurogenic claudication. Neurology, 2015, 85, 1250-1256. | 1.1 | 14 |
| 60 | Associations between a patient-reported outcome (PRO) measure of sarcopenia and falls, functional status, and physical performance in older patients with cancer. Journal of Geriatric Oncology, 2015, 6, 433-441. | 1.0 | 23 |
| 61 | Data Interpretation in Analgesic Clinical Trials With Statistically Nonsignificant Primary Analyses: An ACTTION Systematic Review. Journal of Pain, 2015, 16, 3-10. | 1.4 | 42 |
| 62 | Reporting of intention-to-treat analyses in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain, 2014, 155, 2714-2719. | 4.2 | 12 |
| 63 | Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain, 2014, 155, 461-466. | 4.2 | 25 |
| 64 | A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Supportive Care in Cancer, 2014, 22, 1807-1814. | 2.2 | 92 |
| 65 | DNA double-strand breaks activate ATM independent of mitochondrial dysfunction in A549 cells. Free Radical Biology and Medicine, 2014, 75, 30-39. | 2.9 | 7 |
| 66 | Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain, 2014, 155, 1871-1877. | 4.2 | 34 |
| 67 | The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. Journal of Pain, 2014, 15, 241-249. | 1.4 | 159 |
| 68 | Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain, 2014, 155, 1683-1695. | 4.2 | 99 |
| 69 | EXCAP exercise to improve fatigue, cardiopulmonary function, and strength: A phase II RCT among older prostate cancer patients receiving radiation and androgen deprivation therapy Journal of Clinical Oncology, 2012, 30, 9010-9010. | 1.6 | 6 |
| 70 | YOCAS yoga for musculoskeletal symptoms in breast cancer patients receiving aromatase inhibitors: A URCC CCOP randomized, controlled clinical trial Journal of Clinical Oncology, 2012, 30, 9028-9028. | 1.6 | 2 |
| 71 | Pain, sleep disturbance, and fatigue symptom cluster in patients suffering from chronic chemotherapy-induced neuropathic pain (CINP) Journal of Clinical Oncology, 2012, 30, 9113-9113. | 1.6 | 2 |
| 72 | Falls, physical performance deficits, and functional losses in cancer survivors with chemotherapy-induced neuropathy (CIPN): A University of Rochester CCOP study Journal of Clinical Oncology, 2012, 30, 9014-9014. | 1.6 | 0 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Physical symptoms and psychological distress in head and neck cancer patients Journal of Clinical Oncology, 2012, 30, e16056-e16056. | 1.6 | Ο |